Background. Patients with hypertrophic cardiomyopathy (HCM) frequently have arrhythmias and hemodynamic abnormalities and are prone to sudden death and syncope. An important need exists for improved risk stratification and definition of appropriate investigation and therapy.
P atients with hypertrophic cardiomyopathy (HCM) are prone to sudden death and syncope.1-10 Sudden death is particularly common in patients with certain clinical characteristics.1-10 Arrhythmias and hemodynamic abnormalities are also prevalent in HCM.1"-32 However, the prognostic significance of many of these findings is unclear. Linked to these issues is the fact that the mechanisms of sudden death and syncope in HCM are not fully known. Therefore, there is a need for improved identification of HCM patients who are at risk for sudden death and a need for better definition of appropriate investigation and therapy.
We have previously shown that sustained ventricular arrhythmia induced at electrophysiological study is strongly associated with a history of cardiac arrest and syncope. 32 The purposes of the present study were 1) to determine the clinical, Holter, hemodynamic, and electrophysiological findings that help to risk-stratify patients with HCM and 2) to assess prospectively the clinical course of a large group of HCM patients considered to be at high risk for sudden death, after adoption of a therapeutic strategy designed to correct major hemodynamic and electrophysiological abnormalities. Such data not only would highlight clinically relevant information but also would provide insights as to underlying mechanisms responsible for sudden death and syncope in HCM.
Methods

Patients
The patient population consisted of 230 consecutive patients with HCM who underwent Holter, cardiac 36 (16%) Family history of sudden death in two or more first-degree relatives 9 (4%) Palpitations 21 (9%) VT, ventricular tachycardia. Cardiac events are sudden death, cardiac arrest, or syncope associated with defibrillator discharge.
catheterization, and electrophysiological studies at the National Institutes of Health between June 1983 and May 1990. The study included 155 patients reported earlier. 32 The clinical presentation of the 230 patients ( Table 1 ) suggested either that they were at high risk for sudden death (prior cardiac arrest,9 syncope or presyncope,89 a strong family history of sudden death,' young age,2-6 or nonsustained ventricular tachycardia [VT] on ambulatory Holter recording '8'19) or that potentially serious arrhythmias might be present (palpitations, the nature of which was undetermined). In all patients, the diagnosis of HCM was based on the echocardiographic demonstration of a hypertrophied nondilated left ventricle in the absence of another cause of left ventricular hypertrophy. Sudden death was defined as death within 1 hour of symptoms, and cardiac arrest was defined as a history of a resuscitation attempt requiring direct-current cardioversion within 30 minutes of collapse. Presyncope was defined as two or more episodes of severe lightheadedness that did not evolve to loss of consciousness. In all patients, cardioactive drugs were discontinued for at least five half-lives before studies under in-hospital observation. The following studies were performed at baseline evaluation: history and physical examination, chest x-ray, 12-lead ECG, M-mode and two-dimensional echocardiograms, 24- 
Relation of Induced Sustained Ventricular Arrhythmia to Clinical Presentation
Patients with a history of cardiac arrest and syncope had the highest prevalence of sustained ventricular arrhythmia induced at electrophysiological study (66% and 38%, respectively, Figure 2 ). In contrast, sustained ventricular arrhythmia was induced in only 16 (Figure 3 ). In contrast, only four of 80 patients with syncope (5%), one of 52 patients with presyncope (2%), and two of 66 patients in whom symptoms of altered consciousness were absent (3%) had a cardiac event.
Hemodynamic parameters. None of the hemodynamic parameters (right and left heart filling pressures, left ventricular outflow tract gradient, or cardiac output) were significantly related to prognosis (Table 2) . Only three patients were treated with amiodarone; in two, the drug was stopped after less than 6 months because of side effects. During a follow-up period of 30+19 months, only one patient (3%) died suddenly (2-year survival rate of 97%, Figure 4A ). This patient (patient 16, Table 4 ) had not benefited from class la or lb antiarrhythmic drugs, had refused to take amiodarone because of its potential side effects, and was considering receiving an automatic defibrillator.
One sudden death (patient 17, Table 4 ) also occurred during follow-up of 30 patients (3%) who had neither symptoms of impaired consciousness nor VT on Holter and who were studied because of either a strong family history of sudden death or palpitations. The 2-year survival rate in this subgroup was also 97% ( Figure 4A) .
Patients with symptoms of impaired consciousness. In contrast to patients without symptoms of impaired consciousness, VT on Holter was of prognostic significance in patients with prior cardiac arrest, syncope, or presyncope: 11 of 79 such patients with nonsustained VT on Holter (14%) had cardiac events versus four of 85 patients (5%) who did not have VT on Holter (p =0.029; Figure 4B and Table 5 ). In this subgroup, the 3-year cardiac event-free rates in patients with VT and in patients without VT on Holter were 96 ±4% and 79±6%, respectively (p=0.057).
Sustained ventricular arrhythmias induced at electrophysiological study. Of the 17 patients who had a cardiac event, 14 (82%) had an inducible sustained ventricular arrhythmia: polymorphic VT in 12 patients (86%) and monomorphic VT in two (14%). The VT was induced with three premature extrastimuli in 10 patients (71%) and two premature extrastimuli in four (29%). The average cycle length of the polymorphic VT was 232±25 msec, and the cycle lengths of the two monomorphic VTs were 235 and 248 msec, respectively.
The 1-year, 2-year, and 5-year cardiac event-free rates in patients with an inducible sustained ventricular arrhythmia were 94±3%, 85+6%, and 48±21%, respectively, compared with 100%, 99±1%, and 92+6%, respectively, in patients without an inducible sustained ventricular arrhythmia (p<0.0001). In contrast to nonsustained VT on Holter, sustained ventricular arrhythmia induced by programmed electrical stimulation was significantly asso- Figure 5A ). The relation of inducibility of ventricular arrhythmia to occurrence of subsequent cardiac events was more significant when the number of premature extrastimuli that was required to induce arrhythmia was taken into consideration: Thus, of 10 patients in whom ventricular arrhythmia was induced with two premature extrastimuli, two (20%) died suddenly compared with none of 56 patients in whom ventricular arrhythmia was not induced with two or fewer premature stimuli-a 2-year survival rate of 80+13% versus 100% (p=0.001).
Interrelation of Nonsustained VT on Holter and Inducibility of Sustained Ventricular Arrhythmia to Subsequent Cardiac Events
Patients with nonsustained VT on Holter with inducible sustained ventricular arrhythmia had the worst prognosis; 10 of 49 such patients (20%) had a cardiac event (p<O.OO1; Figure 6 and Table 5 Figure 1 .
Probably as a consequence of this aggressive therapeutic management, the annual incidence of sudden death (1.8% at 5 years of follow-up) was far less than that predicted by the patients' clinical characteristics. A total of 17 cardiac events (sudden death, cardiac arrest, or syncope associated with electric discharge by an automatic defibrillator presumably as a consequence of a ventricular arrhythmia that in the absence of the device would have resulted in sudden death) occurred during the follow-up period. Fourteen (82%) of these 17 cardiac events were in patients with inducible sustained VT. Notably, in 11 (79%), the induced arrhythmia was sustained polymorphic VT, and in nine (64%), the VT was induced only with introduction of three premature extrastimuli. These findings confirm the appropriateness of our electrical stimulation protocol and provide further evidence of the relevance of induced sustained VT, whether monomorphic or polymorphic, in predicting subsequent cardiac events.
Importantly, of all the variables examined, only two were significant and important independent predictors of long-term outcome -induction of a sustained VT at baseline electrophysiological study and a history of cardiac arrest or syncope. Thus, the annual incidence of cardiac events in patients with inducible sustained VT was about 7% compared with <1% in patients in whom ventricular arrhythmia was not induced at electrophysiological study. The relation of inducibility of sustained ventricular arrhythmia to subsequent incidence of cardiac events was significant in patients with prior cardiac arrest, syncope, or presyncope as well as in patients in whom symptoms of impaired consciousness were absent. Notably, none of 56 patients who did not have symptoms of impaired consciousness and in whom a sustained VT was not induced with two or fewer premature extrastimuli had a cardiac event during follow-up.
In contrast to the predictive value of sustained ventricular arrhythmia induced by programmed electrical stimulation, nonsustained VT on Holter was indicative of increased risk only in patients with symptoms of impaired consciousness. Indeed, the prognosis in patients without symptoms of impaired consciousness who did not have an inducible ventricular arrhythmia was benign (annual incidence of cardiac events of <1%) irrespective of the presence or absence of nonsustained VT on Holter. This benign prognosis occurred despite the fact that only a minority of the patients were treated with antiarrhythmic drugs, including amiodarone. It is worth emphasizing, however, that about 20% of the patients in whom symptoms of impaired consciousness were absent were treated with antiarrhythmic drugs because of induction of sustained VT with only two premature extrastimuli. Some of these patients might have died if inducible sustained VT had not been detected and treated. Hence, there may be a role for electrophysiologically guided antiarrhythmic therapy in this subgroup of patients.
Conclusions
HCM patients with a history of cardiac arrest or syncope are at high risk for subsequent cardiac events from several potential mechanisms and should be investigated and treated vigorously. In addition to Holter monitoring, appropriate investigation in this subgroup of patients includes thallium scintigraphy to identify patients with exercise-induced myocardial ischemia and electrophysiological studies to determine bradyarrythmias and tachyarrhythmias.
In the absence of symptoms of impaired consciousness, induction of a sustained ventricular arrhythmia at electrophysiological study with two or fewer premature stimuli probably identifies most patients who are at risk of sudden death. As the incidence of sudden death in asymptomatic or mildly symptomatic patients is relatively low, however, electrophysiological studies should probably be tailored to individual needs (athletes, pilots, etc.).
The significance of nonsustained VT on Holter in HCM depends on the clinical presentation and whether a sustained ventricular arrhythmia can be induced during programmed electrical stimulation -nonsustained VT on Holter observed in patients who have neither symptoms of impaired consciousness nor sustained VT induced by programmed electrical stimulation is of benign prognostic significance even in the absence of antiarrhythmic therapy.
Finally, a detailed clinical, Holter, treadmill-exercisestudy, exercise 201T1 scintigraphy, cardiac catheterization, and electrophysiological evaluation in high-risk patients, together with a therapeutic strategy (Figure 1 ) that corrects major abnormal hemodynamic and electrophysiological findings, promises to reduce the incidence of sudden death to <2% per year.
